Efficacy of Intravenous Cyclophosphamide and Mycophenolate Mofetil for Treating Pediatric Lupus Nephritis in Resource-Constrained Environments - Takeaways - MDSpire

Efficacy of Intravenous Cyclophosphamide and Mycophenolate Mofetil for Treating Pediatric Lupus Nephritis in Resource-Constrained Environments

  • By

  • Adrienne Katrin M. Guiang-Valerio

  • Ma. Theresa M. Collante

  • Christine B. Bernal

  • February 24, 2026

  • 0 min

Share

  • 1

    Systemic lupus erythematosus in children has a high incidence of lupus nephritis, particularly affecting Asian populations.

  • 2

    Cyclophosphamide and mycophenolate mofetil are first-line treatments for pediatric lupus nephritis according to current guidelines.

  • 3

    This study aimed to compare the effectiveness of CYC and MMF in Filipino children with lupus nephritis.

  • 4

    Treatment switching was defined as any modification of the induction regimen due to inadequate response or adverse effects.

  • 5

    The study utilized a retrospective cohort design, analyzing data from pediatric patients diagnosed with lupus nephritis.

Original Source(s)

Efficacy of Intravenous Cyclophosphamide and Mycophenolate Mofetil for Treating Pediatric Lupus Nephritis in Resource-Constrained Environments

  • by Adrienne Katrin M. Guiang-Valerio, Ma. Theresa M. Collante, Christine B. Bernal

  • February 24, 2026

Related Content

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.